Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAP 2003

Next Previous
Drug Profile

CAP 2003

Alternative Names: CAP-2003; CDC-exosomes

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capricor Therapeutics
  • Developer Capricor Therapeutics; Cedars-Sinai Health System
  • Class Anti-inflammatories; Antifibrotics; Apoptosis regulatory proteins; Biological proteins; Cardiovascular therapies; Exosome therapies; Eye disorder therapies; MicroRNAs; RNA
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cardiovascular disorders; Duchenne muscular dystrophy; Fibrosis; Graft-versus-host disease; Inflammation

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral)
  • 10 Apr 2023 CAP 2003 is still in preclinical trials for Duchhene Muscular dystrophy (Capricor Therapeutics pipeline, April 2023)
  • 28 Jul 2022 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top